Blu – AMD

Blu

Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.

Aprile 2, 2026 Alice Lione

The adverse effects associated with tirzepatide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis

Sillassen CDB, Faltermeier P, Bjerg JL, et al.
BMC Med. Pub. online 27 Mar 2026.

Leggi

Aprile 2, 2026 Alice Lione

Safety of semaglutide after dialysis initiation: an individual-level pooled analysis

Klein KR, Menacher A, Buse JB, et al.
Diabetes Care. Pub. online 26 Mar 2026.

Leggi

Aprile 2, 2026 Alice Lione

Evolocumab to reduce first major cardiovascular events in patients without known significant atherosclerosis and with diabetes: results from the VESALIUS-CV trial

Marston NA, Bohula EA, Bhatia AK, et al.
JAMA. Pub. online 28 Mar 2026.

Leggi

Aprile 2, 2026 Alice Lione

Cardiorenal outcomes with tirzepatide compared with dulaglutide in patients with diabetes and cardiovascular disease: a post hoc analysis of the SURPASS-CVOT randomized clinical trial

Nissen SE, Wolski K, D’Alessio D, et al.
JAMA Cardiol. Pub. online 28 Mar 2026.

Leggi

Aprile 2, 2026 Alice Lione

Metabolic and bariatric surgery for patients with obesity type 1 diabetes mellitus: a comprehensive updated systematic review and meta-analysis

Mitchell S, Patwardhan K, Lucocq J, et al.
Diabet Med. Pub. online 28 Mar 2026.

Leggi

Aprile 2, 2026 Alice Lione

Lower risk of cardiovascular events in patients with clinical atherosclerotic cardiovascular disease who initiated semaglutide 2.4 mg in the real-world: results from the SCORE—clinical ASCVD study

Nanna MG, Mena-Hurtado C, Divino V, et al.
Diabetes Obes Metab. Pub. online 26 Mar 2026.

Leggi

Aprile 2, 2026 Alice Lione

Lean mass changes with incretin therapy versus lifestyle intervention: a systematic review and meta‐analysis of randomised controlled trials

Eisa N, Barood O
Diabetes Obes Metab. Pub. online 24 Mar 2026.

Leggi

Aprile 2, 2026 Alice Lione

Waist-to-height ratio and the risk of cardiovascular outcomes and mortality in type 2 diabetes with and without abdominal obesity

Park KY, Han K, Park JH, et al.
Diabetes Obes Metab. Pub. online 24 Mar 2026.

Leggi

Marzo 29, 2026 Alice Lione

Oral semaglutide and change in cardiovascular risk factors in high-risk type 2 diabetes: a post hoc secondary analysis of the SOUL randomized clinical trial

Mulvagh SL, Inzucchi SE, Marx N, et al.
JAMA Cardiol. Pub. Online 25 Mar 2026.

Leggi

Marzo 29, 2026 Alice Lione

Quality-score (Q-Score) can be more sensitive than %time in range and several other CGM metrics in detecting responses to therapeutic interventions

Rodbard D, Augstein P, Heinke P, et al.
Diabetes Technol Ther. Pub. Online 27 Mar 2026.

Leggi